The Valley Desk

NCT00603668 · Interventional trial

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Overall registry status Completed

Phase 1 · Phase 2

Conditions Chronic Lymphocytic Lymphoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov